Tricida, Inc.
TCDA

$5.95 M
Marketcap
$0.11
Share price
Country
$0.00
Change (1 day)
$13.85
Year High
$0.04
Year Low
Categories

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

marketcap

Tricida, Inc. (TCDA) - Company Outlook



Company Outlook

Year Receivables Debt Liabilities Assets Current Assets
2021 120.43 M 168.29 M 168.51 M 145.54 M
2020 -122,732,000 242.81 M 315.13 M 314.02 M
2019 40.87 M 107.94 M 371.83 M 312.74 M
2018 204.81 M 53.32 M 247.85 M 244.35 M
2017 -9,858,000 11.44 M 70.66 M 69.51 M